Vanguard Asset Management’s NovoCure NVCR Stock Holding History

Vanguard Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Hold	97,534	–	–	﹤0.01%	1696
2026 Q1	$1.06M	Buy	+97,534	New	+$1.22M	﹤0.01%	1765

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Asset Management's NVCR Position: Q2 2026 in Review

Vanguard Asset Management held its NovoCure (NVCR) position steady in Q2 2026 at 97,534 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1696.

Vanguard Asset Management first reported a position in NVCR in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Vanguard Asset Management held 97,534 shares of NovoCure worth $1.48M as of Q2 2026.
Vanguard Asset Management left its NovoCure share count unchanged in Q2 2026.
NovoCure made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1696 holding.
Vanguard Asset Management first reported a position in NovoCure in Q1 2026 and has held it in 2 quarters since.
212 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.